In patients with adenocarcinoma, EGFR, ALK, and ROS1 mutations as well as PD-L1 expression were mostly tested using single biomarker assays, such as Sanger sequencing, reverse transcriptase-polymerase chain reaction, immunohistochemistry, and fluorescent in situ hybridization. This evidence concerns the gene ALK and adenocarcinoma.